Nice | Empagliflozin in Type 2 Diabetes

5th June 2015 by Louise Hudman

Nice | Empagliflozin in Type 2 Diabetes

This is a new guideline from Nice. Empagliflozin is a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, which blocks glucose reabsorption in the kidneys and so causes increased urinary excretion. For other SGLT-2 inhibitors have been approved by NICE, see my post about Dapagliflozin.

Empagliflozin use in Type 2 Diabetes

  • as a 2nd drug in combination with metformin if they
    • can not take sulphonylureas.
    • are at significant risk of hypoglycaemia or its consequences.
  • as a 3rd drug with metformin and either a sulphonylurea or a thiazolinedione.
  • in combination with insulin with or without other drugs.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"...the NASGP LocumDeck service makes my running things as a self employed GP almost effortless - I don't think I would want to work without it. Invoicing is streamlined and the website is very user-friendly. After a sometimes busy week at work the last thing you want is to spend hours on business admin - LocumDeck is a real timesaver."

Dr James O’Mahony on LocumDeck

See the full list of features within our NASGP membership plans

Membership